A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 7
- Registration Number
- NCT02918331
A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 202
- Registration Number
- NCT02918318
Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Registration Number
- NCT02895815
- Locations
- 🇯🇵
Kyorin University Hospital, Mitaka, Japan
🇯🇵Tokyo Women's Medical University Hospital, Tokyo, Japan
🇯🇵Yokohama City University Medical Center, Yokohama, Japan
Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 18
- Registration Number
- NCT02835508
A Study to Evaluate the Safety and Immunogenicity of Different Doses of ExPEC4V (JNJ-63871860) in Healthy Japanese Adult Participants
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2016-10-04
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 48
- Registration Number
- NCT02748967
An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 159
- Registration Number
- NCT02641730
A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 8
- Registration Number
- NCT02556892
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 24
- Registration Number
- NCT02555124
A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male Participants
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-08-20
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 8
- Registration Number
- NCT02530060
A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 8
- Registration Number
- NCT02497378
© Copyright 2024. All Rights Reserved by MedPath